These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39399100)

  • 1. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
    Derfuss T; Bermel R; Lin CJ; Hauser SL; Kappos L; Vollmer T; Comi G; Giovannoni G; Hartung HP; Weber MS; Wang J; Jessop N; Chognot C; Craveiro L; Bar-Or A
    Ther Adv Neurol Disord; 2024; 17():17562864241277736. PubMed ID: 39399100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Hauser SL; Kappos L; Montalban X; Craveiro L; Chognot C; Hughes R; Koendgen H; Pasquarelli N; Pradhan A; Prajapati K; Wolinsky JS
    Neurology; 2021 Oct; 97(16):e1546-e1559. PubMed ID: 34475123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    Foong YC; Merlo D; Gresle M; Buzzard K; Zhong M; Yeh WZ; Jokubaitis V; Monif M; Skibina O; Ozakbas S; Patti F; Grammond P; Amato MP; Kalincik T; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Lechner Scott J; Boz C; Sa MJ; Butzkueven H; van der Walt A; Zhu C;
    J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):767-774. PubMed ID: 38453478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.
    Smoot K; Chen C; Stuchiner T; Lucas L; Grote L; Cohan S
    BMJ Neurol Open; 2021; 3(2):e000108. PubMed ID: 34308352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
    Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study.
    Weber MS; Buttmann M; Meuth SG; Dirks P; Muros-Le Rouzic E; Eggebrecht JC; Hieke-Schulz S; Leemhuis J; Ziemssen T
    Front Neurol; 2022; 13():863105. PubMed ID: 35614917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab for multiple sclerosis.
    Lin M; Zhang J; Zhang Y; Luo J; Shi S
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.
    Knapp R; Hardtstock F; Wilke T; Maywald U; Chognot C; Craveiro L; Rouzic EM
    Mult Scler Relat Disord; 2023 Apr; 72():104583. PubMed ID: 36905817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
    Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
    BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
    Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
    Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.